Bristol-Myers Squibb, Otsuka Pharma Sprycel Receives FDA Priority Review
Additionally, BMS and Otsuka Pharma have received a priority review designation from the FDA for the sNDA. Sprycel, an oral BCR-ABL inhibitor, is currently approved by the FDA
HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).